Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study

Completed

• Conditions: hypertensie; High blood pressure; Hypertension

• Registration Number: NL-OMON37880
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

Age between 18 and 75 yrs
Treatment-reistant hypertension
Willingness to give written informed consent

Exclusion Criteria

Secondary forms of hypertension
Renal arteries not accessible to intervention
Suboptimal dosing of anthypertensive medication
White coat hypertension
Pregnancy
Renal insufficiency (GFR < 45 ml/min

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in 24-hour ambulatory blood pressure decrease between the RFSD and<br /><br>spironolactone group. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Proportion of patients per intervention group with normalization of their<br /><br>24-hour ambulatory blood pressure<br /><br>- Proportion of patients per intervention group with a decrease in 24-hour<br /><br>ambulatory blood pressure of >= 10 mmHg systolic and >= 5 mmHg diastolic.<br /><br>- Cost effective of RFSD<br /><br>- Difference in scores of quality of llife between RFSD and spironolactone group<br /><br>- Predictive value of clonidine-suppressiontest for the blood pressure response<br /><br>to RFSD</p><br>